Spironolactone (drug)
Sponsors
Emory University, Universidad de los Andes, Chile, University Medical Center Groningen, University of Sao Paulo General Hospital, Starlight Therapeutics Inc.
Conditions
AnemiaAortic StenosisCKDCardiovascular DiseasesCongenital DisordersDiabetic Kidney DiseaseGlioblastoma (GBM)HIV
Phase 1
Phase 2
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
RecruitingNCT07304817
Start: 2026-05-12End: 2028-02-01Target: 100Updated: 2026-05-29
Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
Not yet recruitingNCT07539259
Start: 2026-12-01End: 2030-02-28Target: 445Updated: 2026-09-11
Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia.
Not yet recruitingNCT07715318
Start: 2026-12-01End: 2028-03-01Target: 40Updated: 2026-07-20
Phase 4
Cardiovascular Protective Effect of Spironolactone in Hemodialysis
NCT00277693
Updated: 2006-01-16
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
Not yet recruitingNCT07523867
Start: 2026-04-01End: 2026-11-01Target: 60Updated: 2026-05-13
SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy
Not yet recruitingNCT07687160
Start: 2026-09-01End: 2028-02-01Target: 30Updated: 2026-07-13